Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 157,084 shares at $0.30 ($47K) on 2026-06-29, disclosed to the SEC on 2026-06-29.
Scheduled sale ($47k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |
| HOWL | SELL | 2026-05-29 | $66K | — | Filing → |